NCT01189461 - Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Anti- VGF InhibitorDiabetic Macular EdemaDiabetic Retinopathy

Interventions

DRUG

pegaptanib sodium

Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.

Trial Locations (12)

15405

Hospital Naval Del Ferrol, Ferrol

15705

Hospital Ntra. Sra. de La Esperanza, Santiago de Compostela

15850

PHSOTEY / Silmätautien klinikka, Lahti

17007

Hospital Universitari de Girona Dr. Josep Trueta, Girona

28040

Hospital Universitario Clinico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

43204

Hospital Universitari Sant Joan de Reus, Reus

70210

Kuopion Yliopistollinen sairaala, Kuopio

114 86

Stockholms Ogonklinik, Stockholm

721 89

Ogonkliniken, Centrallasarettet, Västerås

GU15 3UW

Frimley Park Hospital, Frimley

SE5 9RS

Kings College Hospital, London